71
Participants
Start Date
December 31, 2015
Primary Completion Date
June 25, 2021
Study Completion Date
December 31, 2025
5Fluorouracile and Mitomycin-C
All the patients will receive radiochemotherapy with two cycles of 5FU (1,000 mg/m²/d with 96-h infusion, days 1-5 and 29-33 of SIB-IMRT) and Mitomycin-C (10 mg/m², days 1 and 29).
Simultaneously integrated boost of intensity modulated radiation therapy (SIB-IMRT) by tomotherapy
SIB-IMRT schedule of 61.2 Gy/1.7 Gy to the primary tumor, 57.60 Gy / 1.6 Gy to involved nodes, and 54 / 1.5 Gy to elective pelvic lymph nodes.
Centre François Baclesse, Caen
Institut de cancérologie de l'Ouest, Saint-Herblain
Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy
Institut de Cancérologie de l'Ouest - Centre Paul Papin, Angers
Centre Léon Berard, Lyon
Centre Antoine Lacassagne, Nice
Centre Paul Strauss, Strasbourg
IUCT-Oncopole, Toulouse
Accuray Incorporated
INDUSTRY
Centre Francois Baclesse
OTHER